Previous 10 | Next 10 |
Regulus Therapeutics press release (NASDAQ:RGLS): Q1 GAAP EPS of -$0.05. Research and development expenses were $3.7M. For further details see: Regulus Therapeutics GAAP EPS of -$0.05
Regulus Therapeutics Reports First Quarter 2022 Financial Results and Recent Updates PR Newswire FDA Acceptance of Investigational New Drug (IND) Application for RGLS8429 for Autosomal Dominant Polycystic Kidney Disease (ADPKD) On track to initiate Phase 1 stud...
AAIC, ACB, ACHV, AFRM, AGRO, AGRX, APDN, APTX, AQN, AVPT, AXU, BANX, BBI, BEAT, BIOL, BLBD, BLND, BOXL, BSQR, CBAY, CDXC, CLLS, CLVR, CODX, COMP, CORZ, CRMD, CTIC, CURI, CWCO, DARE, DUOL, EDR, ETON, EYEN, FIGS, GPL, GWH, HLI, HTGM, IBIO, IDN, OTCQB:IGXT, IMMR, INDI, INTZ, INUV, JOBY, KMPH, LC...
3 Penny Stocks to Add to Your Watchlist That Are Climbing Today With another interesting day of trading penny stocks and blue chips, there is a lot for investors to know. During trading on May 11th, investors digested news of worse-than-expected inflation data. The data showed that the ...
The shares of Regulus Therapeutics (NASDAQ:RGLS) have recorded the second-best intraday gain ever on Wednesday after the clinical stage biotech announced that the FDA accepted its Investigational New Drug Application for RGLS8429 in a form of hereditary kidney disorder. The IND was intended t...
Regulus Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire Company remains on track to initiate Phase 1 clinical study in second quarter ...
Regulus Therapeutics Announces Timing for First Quarter 2022 Financial Results Webcast and Conference Call PR Newswire SAN DIEGO , May 5, 2022 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the di...
Regulus Therapeutics Announces Initiation of Preclinical Studies in Amyotrophic Lateral Sclerosis under a Collaboration Agreement with Harvard's Brigham and Women's Hospital PR Newswire - Preliminary data are expected in the second half of 2022 SAN DIEGO ...
Regulus Therapeutics Inc. (RGLS) Q4 2022 Earnings Conference Call March 10, 2022, 05:00 PM ET Company Participants Cris Calsada - Chief Financial Officer Jay Hagan - President and Chief Executive Officer Denis Drygin - Chief Scientific Officer Conference Call Participants Brian Cheng - Cantor...
Regulus Therapeutics press release (NASDAQ:RGLS): Q4 GAAP EPS of -$0.07. As of December 31, 2021, Regulus had $60.4M in cash and cash equivalents. For further details see: Regulus Therapeutics GAAP EPS of -$0.07
News, Short Squeeze, Breakout and More Instantly...
Regulus Therapeutics Inc. Company Name:
RGLS Stock Symbol:
NASDAQ Market:
Regulus Therapeutics Inc. Website:
Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire Continued mechanistic dose resp...
Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes PR Newswire SAN DIEGO , June 4, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and devel...
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer PR Newswire SAN DIEGO , May 16, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of inn...